Prosmaxx drug use

Prosmaxx has the main ingredient in the cephalosporin group of antibiotics. This is a semi-synthetic antibiotic, used to treat pneumonia, otitis media, strep throat, and cellulitis.

Prosmaxx has the main ingredient Cefdinir, also known by another scientific name, Omnicef, with a content of 125mg/5ml.
Main ingredient Cefdinir is a bactericidal agent that treats infections caused by bacteria by interfering with cell wall synthesis. Cefdinir has broad-spectrum activity against a wide range of infections caused by gram-positive and gram-negative bacteria.
Prosmaxx is often prescribed by doctors to treat mild to moderate infections caused by some Gram-negative and Gram-positive bacteria such as:
Acute maxillary sinusitis Skin and skin structure infections that do not change Symptoms caused by Staphylococcus aureus and Streptococcus pyogenes Acute bacterial otitis media Pharyngitis and tonsillitis caused by Streptococcus pyogenes strains Community acquired pneumonia caused by bacteria such as Haemophilus influenzae, Haemophilus parainfluenzae, Streptococcus pneumoniae and Streptococcus pneumoniae. Moraxella catarrhalis. Ear, nose and throat diseases caused by acute bacteria such as Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae Note : Prosmaxx will not work against infections caused by viruses including the common cold, flu.
Do not use the drug in patients who are allergic to cefdinir and other antibiotics of the cephalosporin and penicillin groups.

The drug is prepared in the form of a powder and is used orally. Patients can take Prosmaxx before or after meals.
Dosage for adults and adolescents (13 years and older)
In the treatment of pneumonia, the dose is 300 mg every 12 hours. In the treatment of acute exacerbations of chronic bronchitis, the drug dosage is 300 mg/12h or 600 mg/24h. In the treatment of acute maxillary sinusitis, the drug dosage is 300mg/12h or 600mg/24h In the treatment of pharyngitis and tonsillitis, the drug dosage is 300mg/12h or 600mg/24h. In the treatment of uncomplicated skin and skin structure infections 300 mg every 12 hours is used. Pediatric patients (6 months to 12 years old)
In the treatment of acute bacterial otitis media, the drug dosage is 7 mg / kg / 12 hours or 14 mg / kg / 24 hours. In the treatment of acute maxillary sinusitis, the drug dose is 7 mg/kg/12 hours or 14 m/kg/24 hours In the treatment of pharyngitis and tonsillitis, the drug dosage is 7 mg/kg/12 hour or 14 mg/kg/24h. In the treatment of uncomplicated skin and skin structure infections, the drug dose is 7 mg / kg / 12 hours For patients with renal failure:
For adult patients with creatinine clearance <30mL / minutes, the dose of cefdinir should be 300 mg, once daily. For pediatric patients with creatinine clearance <30 mL/min, the recommended dose of cefdinir is 7 mg/kg (maximum 300 mg) administered once daily. Patients on hemodialysis
In patients maintained on chronic hemodialysis, the recommended initial dosing regimen is 300 mg or 7 mg/kg every other day. At the end of each hemodialysis session, the maintenance dose is 300 mg (or 7 mg/kg). Subsequent doses are then given every other day. When using an overdose of the drug, the patient will experience the usual signs of poisoning such as nausea, vomiting, epigastric pain, diarrhea, convulsions.
How to handle: The doctor will prescribe dialysis in case of high level of cefdinir overdose, especially in case the patient has problems related to impaired kidney function.

Studies have shown that the majority of side effects are mild and no death or permanent disability has been caused by Prosmaxx. Some side effects that affect the patient's health during the use of the drug include:
Common side effects include diarrhea, nausea, headache, abdominal pain, rash. More serious side effects may occur with the use of Cephalosporin antibiotics Clostridioides difficile infections, anaphylaxis and Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, renal dysfunction, Toxic nephropathy, liver dysfunction including cholestasis, aplastic anemia, hemolytic anemia, hemorrhage, false-positive test for glucoseuria, neutropenia, leukopenia, and leukopenia seed.

As with other broad-spectrum antibiotics, prolonged use of Prosmaxx may lead to the emergence and overgrowth of resistant organisms. If superinfection occurs during therapy, appropriate alternative therapy should be instituted. Cefdinir, like other broad-spectrum antibiotics (antibiotics), should be prescribed with caution in people with a history of colitis. In patients with renal impairment with creatinine clearance less than 30 mL/min, the total daily dose of the drug should be reduced. Because high and prolonged plasma concentrations of cefdinir can lead to undesirable side effects. For pregnant women: Prosmaxx is classified as a class B drug, which may pose a risk. Several studies were conducted in rats and rabbits at doses up to 1000 mg/kg/day, 70 times the human dose on a mg/kg/day basis, or in rabbits at oral doses up to 10 mg/kg/day. 0.7 times higher than the human dose based on mg/kg/day, the results showed that the drug was not teratogenic. However, there are no adequate and well-controlled studies in pregnant women. Therefore, this medicine should be used during pregnancy only when clearly needed. For women who are breast-feeding: Consult a doctor before use. Safety and efficacy in neonates and infants under 6 months of age have not been established. Therefore, do not use the drug for these cases. Geriatric conditions: Cefdinir is well tolerated at all ages, therefore no dose adjustment is required in elderly patients unless renal function is compromised.

Antacids (containing aluminum or magnesium): Concomitant administration of Prosmaxx with antacids may decrease the rate (Cmax) and extent (AUC) of the absorption of these drugs. If an antacid is required during treatment with Prosmaxx, Prosmaxx should be taken at least 2 hours before or after the antacid. Probenecid: As with other β-lactam antibiotics, probenecid inhibits renal excretion of Prosmaxx, resulting in a doubling of peak plasma concentrations of cefdinir and a prolongation of its elimination. Iron supplements and iron-fortified foods: Concomitant use of cefdinir with iron supplements or elemental iron supplements reduces the extent of drug absorption. If iron supplementation is required during Prosmaxx treatment, Prosmaxx should be taken at least 2 hours before or after supplementation. Effects on Test Results: The use of cefdinir may result in a false-positive reaction for glucose in the urine when using Clinitest, Benedict's solution or Fehling's solution. Abciximab: The therapeutic efficacy of Abciximab may be reduced when used in combination with Cefdinir. Aceclofenac: Aceclofenac may decrease the rate of excretion of Cefdinir, resulting in higher serum drug concentrations than Acenocoumarol: The risk or severity of bleeding may be increased when Cefdinir is combined with Acenocoumarol Acetazolamide: Acetazolamide may increase the rate of excretion of cefdinir, may decrease serum concentrations and potentially decrease its effectiveness. Acetylsalicylic Acid: The excretion of Cefdinir may be reduced when combined with Acetylsalicylic acid. Almasilate: The therapeutic efficacy of Cefdinir may be reduced when used in combination with Almasilate.